Injectable semaglutide has shown a maximum relative infant dose of 1.26 percent in available research, well below the 10 percent threshold generally considered safe for breastfeeding
The new GLP analogue had the advantage that it lasted for 160 hours in the body, a two-thousand fold increase in the half-life of liraglutide compared to natural GLP-1
For patients currently using licensed injectable GLP-1 receptor agonists in the UK: Once-daily formulations include liraglutide (Victoza) [2] Once-weekly formulations include semaglutide (Ozempic), dulaglutide (Trulicity), and exenatide extended-release (Bydureon) [1] [2] If you are participating in a clinical trial involving a GLP-1 patch, you must strictly follow the specific instructions provided by the research team regarding application duration, replacement schedule, and all other aspects of use
Starting a GLP-1RA appears associated with reduced risk of incident alcohol use, and possibly reduced opioid, cocaine, and nicotine use
doi: 10.1152/ajpendo.00446.2012 38 KooijmanSWangYParlevlietETBoonMREdelschaapDSnaterseGet al